The shadow of generic challenges has consistently loomed around copyright’s blockbuster drug, Viagra, triggering questions about the prospects of connected drug portfolios. While initial years saw significant returns, the exclusivity end has created the way for discounted alternatives, potentially reducing revenue and creating a real hazard for … Read More